News & Updates

Cefmetazole and cefoxitin prove to be effective in the treatment of patients with urinary tract infections (UTIs) due to extended-spectrum beta-lactamase (ESBL)–producing Escherichia coli, according to two separate studies presented at IDWeek 2022.

Some social needs that are not properly addressed may contribute to the presence of overactive bladder (OAB) in adults, and these unmet needs can affect the overall management of OAB patients, suggests a recent study.

In the 3-year follow-up of the EMPOWER-Lung 1 study, first-line cemiplimab continued to outdo chemotherapy (CT) in providing survival benefit for patients with advanced non-small-cell lung cancer (NSCLC). Moreover, in the second-line setting (patients with progressive disease [PD]), cemiplimab added to CT provided meaningful and durable objective response rate (ORR) and overall survival (OS) benefit.

While rare, infection with antibiotic-resistant gram-negative bacteria (AR-GNB) following a positive COVID-19 diagnosis is more severe and often results in worse outcomes, according to a study presented at the recent Virtual ID Week 2022.

In a real-world, territory-wide, propensity score (PS)–matched study during Hong Kong’s Omicron BA.2.2 wave, early initiation of molnupiravir or nirmatrelvir/ritonavir is shown to reduce the risks of mortality and in-hospital outcomes among community-dwelling outpatients with COVID-19. However, the risk of hospitalization is lowered with nirmatrelvir/ritonavir but not molnupiravir.

The use of a cerebral embolic protection (CEP) device did not reduce the risk of periprocedural stroke in patients undergoing transcatheter aortic valve replacement (TAVR), according to results of the PROTECTED TAVR study presented at TCT 2022.